195 related articles for article (PubMed ID: 24370606)
1. Comparison of the risks of shopping behavior and opioid abuse between tapentadol and oxycodone and association of shopping behavior and opioid abuse.
Cepeda MS; Fife D; Kihm MA; Mastrogiovanni G; Yuan Y
Clin J Pain; 2014 Dec; 30(12):1051-6. PubMed ID: 24370606
[TBL] [Abstract][Full Text] [Related]
2. Comparison of opioid doctor shopping for tapentadol and oxycodone: a cohort study.
Cepeda MS; Fife D; Vo L; Mastrogiovanni G; Yuan Y
J Pain; 2013 Feb; 14(2):158-64. PubMed ID: 23253635
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the risks of opioid abuse or dependence between tapentadol and oxycodone: results from a cohort study.
Cepeda MS; Fife D; Ma Q; Ryan PB
J Pain; 2013 Oct; 14(10):1227-41. PubMed ID: 23850177
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the abuse of tapentadol immediate release: the first 24 months.
Dart RC; Cicero TJ; Surratt HL; Rosenblum A; Bartelson BB; Adams EH
J Opioid Manag; 2012; 8(6):395-402. PubMed ID: 23264317
[TBL] [Abstract][Full Text] [Related]
5. Does tapentadol affect sex hormone concentrations differently from morphine and oxycodone? An initial assessment and possible implications for opioid-induced androgen deficiency.
Eichenbaum G; Göhler K; Etropolski M; Steigerwald I; Pergolizzi J; Kim M; Vorsanger G
J Opioid Manag; 2015; 11(3):211-27. PubMed ID: 25985806
[TBL] [Abstract][Full Text] [Related]
6. Assessing opioid shopping behaviour: a large cohort study from a medication dispensing database in the US.
Cepeda MS; Fife D; Chow W; Mastrogiovanni G; Henderson SC
Drug Saf; 2012 Apr; 35(4):325-34. PubMed ID: 22339505
[TBL] [Abstract][Full Text] [Related]
7. Decreased diversion by doctor-shopping for a reformulated extended release oxycodone product (OxyContin).
Chilcoat HD; Coplan PM; Harikrishnan V; Alexander L
Drug Alcohol Depend; 2016 Aug; 165():221-8. PubMed ID: 27372220
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Tapentadol API Abuse Liability With the Researched Abuse, Diversion and Addiction-Related Surveillance System.
Vosburg SK; Severtson SG; Dart RC; Cicero TJ; Kurtz SP; Parrino MW; Green JL
J Pain; 2018 Apr; 19(4):439-453. PubMed ID: 29224919
[TBL] [Abstract][Full Text] [Related]
9. Bowel function after tapentadol and oxycodone immediate release (IR) treatment in patients with low back or osteoarthritis pain.
Kwong WJ; Hammond G; Upmalis D; Okamoto A; Yang M; Kavanagh S
Clin J Pain; 2013 Aug; 29(8):664-72. PubMed ID: 23835764
[TBL] [Abstract][Full Text] [Related]
10. Opioid shopping behavior: how often, how soon, which drugs, and what payment method.
Cepeda MS; Fife D; Chow W; Mastrogiovanni G; Henderson SC
J Clin Pharmacol; 2013 Jan; 53(1):112-7. PubMed ID: 23400751
[TBL] [Abstract][Full Text] [Related]
11. Effect of discharge opioid on persistent postoperative opioid use: a retrospective cohort study comparing tapentadol with oxycodone.
Lam T; Xia T; Biggs N; Treloar M; Cheng O; Kabu K; Stevens JA; Evans JD; da Gama ME; Lubman DI; Nielsen S
Anaesthesia; 2023 Apr; 78(4):420-431. PubMed ID: 36535726
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study.
Hartrick C; Van Hove I; Stegmann JU; Oh C; Upmalis D
Clin Ther; 2009 Feb; 31(2):260-71. PubMed ID: 19302899
[TBL] [Abstract][Full Text] [Related]
13. Post hoc analyses of data from a 90-day clinical trial evaluating the tolerability and efficacy of tapentadol immediate release and oxycodone immediate release for the relief of moderate to severe pain in elderly and nonelderly patients.
Vorsanger G; Xiang J; Biondi D; Upmalis D; Delfgaauw J; Allard R; Moskovitz B
Pain Res Manag; 2011; 16(4):245-51. PubMed ID: 22059194
[TBL] [Abstract][Full Text] [Related]
14. Bone fractures in patients using tapentadol or oxycodone: an exploratory US claims database study.
Morlion BJ; Margarit C; Wild I; Karra R; Liedgens H; Sohns M; Finco G
Pain Manag; 2021 Jan; 11(1):39-47. PubMed ID: 32996831
[No Abstract] [Full Text] [Related]
15. [Undesired side effects of tapentadol in comparison to oxycodone. A meta-analysis of randomized controlled comparative studies].
Merker M; Dinges G; Koch T; Kranke P; Morin AM
Schmerz; 2012 Feb; 26(1):16-26. PubMed ID: 22366930
[TBL] [Abstract][Full Text] [Related]
16. Gastrointestinal Adverse Events in Hospitalized Patients Following Orthopedic Surgery: Tapentadol Immediate Release Versus Oxycodone Immediate Release.
Wang X; Narayan SW; Penm J; Johnstone C; Patanwala AE
Pain Physician; 2021 May; 24(3):E309-E315. PubMed ID: 33988952
[TBL] [Abstract][Full Text] [Related]
17. Immediate-release tapentadol or oxycodone for treatment of acute postoperative pain after elective arthroscopic shoulder surgery: a randomized, phase IIIb study.
Vorsanger GJ; Klopfer AM; Xiang J; Benson CJ; Moskovitz BL; Rosenthal NR
J Opioid Manag; 2013; 9(4):281-90. PubMed ID: 24353022
[TBL] [Abstract][Full Text] [Related]
18. Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochloride.
Etropolski M; Kelly K; Okamoto A; Rauschkolb C
Adv Ther; 2011 May; 28(5):401-17. PubMed ID: 21494892
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of study discontinuations with tapentadol inmmediate release and oxycodone immediate release in patients with low back or osteoarthritis pain.
Vorsanger G; Xiang J; Okamoto A; Upmalis D; Moskovitz B
J Opioid Manag; 2010; 6(3):169-79. PubMed ID: 20642246
[TBL] [Abstract][Full Text] [Related]
20. Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study.
Hale M; Upmalis D; Okamoto A; Lange C; Rauschkolb C
Curr Med Res Opin; 2009 May; 25(5):1095-104. PubMed ID: 19301989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
